| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The primary target of EBOV-IN-1 is the Ebola virus, specifically inhibiting viral entry or replication. The compound likely targets a viral protein essential for the virus life cycle, such as the glycoprotein (GP) involved in host cell entry or the viral polymerase. Inhibition of these targets prevents viral infection and spread. The precise molecular target and binding mechanism require further elucidation through biochemical and structural studies.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated the antiviral activity of EBOV-IN-1 against Ebola virus in cell culture systems. The compound inhibits viral replication in infected cells, with efficacy measured by reduction in viral titers or viral protein expression. Specific IC₅₀ values for EBOV-IN-1 have not been extensively reported in the available literature. The compound's activity against other filoviruses or related viruses may also have been evaluated.
|
| ln Vivo |
In vivo efficacy of EBOV-IN-1 has been evaluated in animal models of Ebola virus infection. Mouse models, guinea pig models, and non-human primate models are commonly used for Ebola antiviral testing. The compound's ability to protect animals from lethal Ebola virus challenge, reduce viral load, and improve survival has been assessed. Specific in vivo data for EBOV-IN-1 have not been extensively reported. Further studies are needed to confirm its therapeutic potential.
|
| Enzyme Assay |
For antiviral activity screening, standard plaque reduction assays or cytopathic effect reduction assays are used. Ebola virus is propagated in Vero E6 or other permissive cell lines. Cells are infected with virus and treated with serial dilutions of EBOV-IN-1. Viral titers are determined by plaque assay, and EC₅₀ values are calculated. For target identification, biochemical assays using recombinant viral proteins may be employed.
|
| Cell Assay |
For in vitro cell-based studies, Vero E6 or other susceptible cell lines are infected with Ebola virus at an appropriate MOI. Cells are treated with serial dilutions of EBOV-IN-1 immediately before, during, or after infection. Antiviral activity is assessed by measuring viral RNA by qRT-PCR, viral protein expression by Western blotting or immunofluorescence, or infectious virus production by plaque assay. Cytotoxicity is assessed in parallel using standard viability assays.
|
| Animal Protocol |
In vivo animal studies for Ebola antivirals typically use mouse models (e.g., BALB/c mice) infected with mouse-adapted Ebola virus. Guinea pig and non-human primate models may also be used for efficacy testing. Test compound is administered via oral, intraperitoneal, or intravenous routes, often beginning before or shortly after infection. Efficacy endpoints include survival, clinical score, weight loss, and viral load in blood and tissues.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of EBOV-IN-1 have not been extensively characterized. As a small molecule antiviral, it is expected to have properties suitable for oral or parenteral administration. Specific PK parameters such as half-life, clearance, volume of distribution, and bioavailability have not been reported. Further pharmacokinetic studies are needed to optimize dosing regimens for in vivo efficacy studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for EBOV-IN-1 are limited. Standard safety assessments including acute toxicity, genotoxicity, and repeated-dose toxicity studies have not been published. Cytotoxicity against mammalian cell lines is typically evaluated in parallel with antiviral activity studies. Safety and tolerability in animal models are important considerations for further development. Comprehensive toxicological evaluation is needed.
|
| References | |
| Additional Infomation |
EBOV-IN-1 is a research compound for Ebola virus antiviral drug discovery. No clinical trials or regulatory approvals have been reported for this compound. It represents a potential lead compound for the development of therapeutics against Ebola virus disease. The compound may be used in research studies to validate viral targets or to optimize antiviral activity through medicinal chemistry. Further development would require extensive preclinical and clinical evaluation.
|
| Molecular Formula |
C34H43N3O5
|
|---|---|
| Molecular Weight |
573.722329378128
|
| Exact Mass |
573.32
|
| CAS # |
1335113-30-8
|
| PubChem CID |
71254944
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.1
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
42
|
| Complexity |
914
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(CC12CC3CC(CC(C3)C1)C2)NCC(N1CCN(CC2=CC=CC=C2OCC2C=CC(C(=O)OC)=CC=2)CC1)=O
|
| InChi Key |
KSISWIVDFITFKQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C34H43N3O5/c1-41-33(40)28-8-6-24(7-9-28)23-42-30-5-3-2-4-29(30)22-36-10-12-37(13-11-36)32(39)21-35-31(38)20-34-17-25-14-26(18-34)16-27(15-25)19-34/h2-9,25-27H,10-23H2,1H3,(H,35,38)
|
| Chemical Name |
methyl 4-[[2-[[4-[2-[[2-(1-adamantyl)acetyl]amino]acetyl]piperazin-1-yl]methyl]phenoxy]methyl]benzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7430 mL | 8.7151 mL | 17.4301 mL | |
| 5 mM | 0.3486 mL | 1.7430 mL | 3.4860 mL | |
| 10 mM | 0.1743 mL | 0.8715 mL | 1.7430 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
